Literature DB >> 18698082

Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia.

Mariel L te Winkel1, Inge M Appel, Rob Pieters, Marry M van den Heuvel-Eibrink.   

Abstract

Coagulation alterations may be involved in osteonecrosis in childhood acute lymphoblastic leukemia. Retrospectively, we evaluated the available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with symptomatic osteonecrosis (median age: 13.8 years, range 4.0-17.2) and 137 without osteonecrosis (median age: 4.9 years, range 1.0-16.7). Coagulation parameters of both groups were similar at diagnosis. After four weeks of treatment including dexamethasone, levels of antithrombin and protein S were significantly less in osteonecrosis-positive than in osteonecrosis-negative patients. Subsequently, after four doses of asparaginase and tapering dexamethasone, these coagulation parameters equally decreased in both groups. Consequently, nadirs of antithrombin and protein S were significantly lower in osteonecrosis-positive than in osteonecrosis-negative patients, even reaching levels below lower normal limits in the osteonecrosis-positive group. A reduced dexamethasone related increase of antithrombin and protein S, and subsequent decline below normal levels after introduction of asparaginase, may result in a hypercoagulable state, contributing to development of symptomatic osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698082     DOI: 10.3324/haematol.12956

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

Review 1.  Osteonecrosis in children after therapy for malignancy.

Authors:  Sue C Kaste; Evguenia J Karimova; Michael D Neel
Journal:  AJR Am J Roentgenol       Date:  2011-05       Impact factor: 3.959

2.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Authors:  C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

3.  Bone marrow necrosis in a girl with Hodgkin's disease.

Authors:  Herwig Lackner; Volker Strenger; Petra Sovinz; Christine Beham-Schmid; Alexander Pilhatsch; Martin Benesch; Wolfgang Schwinger; Raphael Ulreich; Sandrin Schmidt; Christian Urban
Journal:  Support Care Cancer       Date:  2012-07-08       Impact factor: 3.603

4.  Incidence, risk factors, and treatment outcome of symptomatic osteonecrosis in Taiwanese children with acute lymphoblastic leukemia: a retrospective cohort study of 245 patients in a single institution.

Authors:  Shih-Hsiang Chen; Tsung-Yen Chang; Tang-Her Jaing; Mel S Lee; Chao-Jan Wang; Iou-Jih Hung; Chao-Ping Yang
Journal:  Int J Hematol       Date:  2015-04-04       Impact factor: 2.490

5.  Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.

Authors:  Leonard A Mattano; Meenakshi Devidas; James B Nachman; Harland N Sather; Stephen P Hunger; Peter G Steinherz; Paul S Gaynon; Nita L Seibel
Journal:  Lancet Oncol       Date:  2012-08-15       Impact factor: 41.316

Review 6.  Osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Marina Kunstreich; Sebastian Kummer; Hans-Juergen Laws; Arndt Borkhardt; Michaela Kuhlen
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

Review 7.  Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.

Authors:  Judith Frances Margolin
Journal:  Eur J Pediatr       Date:  2011-02-25       Impact factor: 3.183

8.  Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients.

Authors:  Vincent Gagné; Anne Aubry-Morin; Maria Plesa; Rachid Abaji; Kateryna Petrykey; Pascal St-Onge; Patrick Beaulieu; Caroline Laverdière; Nathalie Alos; Jean-Marie Leclerc; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Lewis B Silverman; Daniel Sinnett; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2019-11-05       Impact factor: 2.533

9.  Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.

Authors:  Marissa A H den Hoed; Saskia M F Pluijm; André G Uitterlinden; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

10.  Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Marissa A H den Hoed; Saskia M F Pluijm; Mariël L te Winkel; Hester A de Groot-Kruseman; Martha Fiocco; Peter Hoogerbrugge; Jan A Leeuw; Marrie C A Bruin; Inge M van der Sluis; Dorien Bresters; Maarten H Lequin; Jan C Roos; Anjo J P Veerman; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2015-09-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.